The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.
Carsten Reinhardt, chief medical officer of Micromet, said: “Having obtained clinical proof of concept for our BiTE antibody technology with MT103 in haematological cancers, we are excited about exploring the potential of MT110 in treating solid tumors. Based on its unique mode of action, MT110 may be suited to treat established tumors as well as disseminated cancer cells, which frequently give rise to metastases.”